{"product_id":"memorial-sloan-kettering-cancer-center-3rd-international-symposium-on-biology","title":"Memorial Sloan Kettering Cancer Center 3rd International Symposium on Biology, Prevention, and Treatment of Toxicities After Transplantation and Cellular Therapy 2023","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003ch3 class=\"product_title entry-title\"\u003eMemorial Sloan Kettering Cancer Center 3rd International Symposium on Biology, Prevention, and Treatment of Toxicities After Transplantation and Cellular Therapy 2023\u003c\/h3\u003e\n\u003cbr\u003eInternational Symposium on Biology\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eInclude: 28 videos + 36 pdfs, size: 16.2 GB\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e Target Audience: hematologist, immunologist, internist, oncologist, critical care physician\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e Sample video: \u003cspan style=\"color: #0000ff;\"\u003e\u003ca href=\"https:\/\/medicalamboss.com\/contact-us\/\" style=\"color: #0000ff;\"\u003econtact me\u003c\/a\u003e\u003c\/span\u003e for sample video\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eDate \u0026amp; Location\u003c\/strong\u003e\u003c\/div\u003e\n\u003cbr\u003eFriday, April 28, 2023, 9:00 AM – Saturday, April 29, 2023, 1:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eSpecialties\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Bone Marrow Transplant, Cellular Therapeutics, Critical Care, Hematology, Immunotherapy, Infectious Diseases, Internal Medicine, Medical Oncology, Pulmonary Medicine, Solid Tumor Oncology\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\n\u003cbr\u003eMemorial Sloan Kettering Cancer Center This 3rd international Symposium will\u003cstrong\u003e bring together a diverse group of experts and thought leaders\u003c\/strong\u003e in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss current advances in the field, mechanisms of toxicities, symptom burden, and late effects after HCT and cellular therapies along with best practices to prevent and treat these complications.\u003cbr\u003e\u003cbr\u003eMemorial Sloan Kettering Cancer Center This unique 2-day program will be comprised of sessions dedicated to a \u003cstrong\u003ewide range of pre-clinical, translational, and clinical topics\u003c\/strong\u003e, including cellular therapies as a model of accelerated aging, CAR T cell-related toxicities, infectious complications, decision science, the role of the gut microbiome in toxicities, debates on how to diagnose and treat difficult complications such as transplant-associated thrombotic microangiopathy, and several keynote lectures from world experts.\u003cbr\u003e\u003cbr\u003eInternational Symposium on Biology\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e\u0026gt;\u0026gt; Who Should Attend\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eThe target audience for this Symposium includes physicians, advanced practice providers (physician assistants and nurse practitioners), and nurses who treat or refer patients for hematopoietic cell transplantation or immune effector cell therapies (i.e., CAR T cells; tumor infiltrating lymphocytes, or T cell receptor therapy).\u003cbr\u003e\u003cbr\u003eAvailable to in-person attendees only, the focus of this optional luncheon session is on \u003cstrong\u003eImproving Outcomes with Active Acute Leukemia Undergoing Transplant  —\u003cem\u003e Do We Need to Reinduce Patients With Active AML?\u003c\/em\u003e\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eDue to space, the luncheon is only available to 50 attendees and selection must be made during course registration. We do recommend early registration in order to secure your spot. Luncheon confirmation will be sent prior to the start of the Symposium.\u003cbr\u003e\u003cbr\u003eWe are pleased to invite the submission of abstracts for this Symposium. Abstracts will be selected on the basis of their scientific merit and content quality. Abstract submission is open to all, and we also highly encourage fellows, residents, pharmacists, and advanced practice providers to submit relevant abstracts in the area of biology, prevention, and treatment of toxicities after transplantation and cellular therapy. In addition, abstracts related to trials and\/or clinical research in progress will be accepted.\u003cbr\u003e\u003cbr\u003eInternational Symposium on Biology\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eIdentify the mechanisms of the most common treatment-related toxicities after HCT and cellular therapy.\u003c\/li\u003e\n\u003cli\u003eDiscuss the best practices in the prevention and treatment of toxicities and symptom burden after HCT and cellular therapy.\u003c\/li\u003e\n\u003cli\u003eCollaborate with a multidisciplinary group of colleagues to discuss, brainstorm, and plan future quality improvement and research efforts to reduce toxicities, improve the patient experience, and decrease non-relapse mortality.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eA New, but Familiar Foe- IEC-HS (HLH).mp4\u003c\/li\u003e\n\u003cli\u003eA New, but Familiar Foe- IEC-HS (HLH).pdf\u003c\/li\u003e\n\u003cli\u003eAbstracts Biopsy proven kidney specific-thrombotic microangiopathy without systemic markers of hemolysis in patients with chronic kidney disease.pdf\u003c\/li\u003e\n\u003cli\u003eAbstracts CAR T-Associated Infection- A Single-Center, Five-Year Retrospective.pdf\u003c\/li\u003e\n\u003cli\u003eAbstracts Connected Care Remote Monitoring after Discharge from Inpatient Autologous or Allogeneic Stem Cell Transplant.pdf\u003c\/li\u003e\n\u003cli\u003eAbstracts Deposition of complement components C5b-9 and MASP2 in tissues is not a feature of GVHD and may assist in discriminating GVHD.pdf\u003c\/li\u003e\n\u003cli\u003eAbstracts Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy- a pharmacovigilance analysis of the FDA reporting system.pdf\u003c\/li\u003e\n\u003cli\u003eAbstracts Encouraging Outcomes after Second Hematopoietic Cell Transplants with Unrelated Cord Blood Grafts for Post-Transplant Relapse in Pediatric Patients.pdf\u003c\/li\u003e\n\u003cli\u003eAbstracts Free interleukin-18 is elevated in CD22 CAR T-cell associated hemophagocytic lymphohistiocytosis-like toxicities.pdf\u003c\/li\u003e\n\u003cli\u003eAbstracts Intrathecal Hydrocortisone for Treatment of Children and Young Adults with CAR T-cell Immune-Effector Cell Associated Neurotoxicity Syndrome.pdf\u003c\/li\u003e\n\u003cli\u003eAbstracts Successful incorporation of electronic patient reported outcomes using PROMIS-29 into standard of care after hematopoietic stem cell transplant.pdf\u003c\/li\u003e\n\u003cli\u003eAdoption or De-adoption of Evidence Into Practice in Transplantation and Cellular Therapy.mp4\u003c\/li\u003e\n\u003cli\u003eAdoption or De-adoption of Evidence Into Practice in Transplantation and Cellular Therapy.pdf\u003c\/li\u003e\n\u003cli\u003eBiomarkers of Aging in BMT and Next Steps in Our Field.mp4\u003c\/li\u003e\n\u003cli\u003eBiomarkers of Aging in BMT and Next Steps in Our Field.pdf\u003c\/li\u003e\n\u003cli\u003eBlocking IFN- Enhancement of CAR T cell Proliferation Without Increasing CRS.pdf\u003c\/li\u003e\n\u003cli\u003eCAR T Toxicities Panel Discussion Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eCAR-HEMATOTOX- Prolonged Cytopenias After CAR T cell Therapy.mp4\u003c\/li\u003e\n\u003cli\u003eCAR-HEMATOTOX- Prolonged Cytopenias After CAR T cell Therapy.pdf\u003c\/li\u003e\n\u003cli\u003eCellular Therapies as a Model of Accelerated Aging Panel Discussion Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eCMV in the Lung- Pathogen, Paradigm, Puzzle.mp4\u003c\/li\u003e\n\u003cli\u003eCMV in the Lung- Pathogen, Paradigm, Puzzle.pdf\u003c\/li\u003e\n\u003cli\u003eCognitive Impacts of Accelerated Aging in BMT.mp4\u003c\/li\u003e\n\u003cli\u003eCognitive Impacts of Accelerated Aging in BMT.pdf\u003c\/li\u003e\n\u003cli\u003eDecision Science and Toxicities Panel Discussion Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eFMT as Prophylactic Supportive Care.mp4\u003c\/li\u003e\n\u003cli\u003eFMT as Prophylactic Supportive Care.pdf\u003c\/li\u003e\n\u003cli\u003eFMT for Treatment of Acute GVHD.mp4\u003c\/li\u003e\n\u003cli\u003eFMT for Treatment of Acute GVHD.pdf\u003c\/li\u003e\n\u003cli\u003eHarmonization of Toxicity Definitions – Challenges – Process and Example.mp4\u003c\/li\u003e\n\u003cli\u003eHarmonization of Toxicity Definitions – Challenges – Process and Example.pdf\u003c\/li\u003e\n\u003cli\u003eHHV-6 Reactivation and Related Complications After HCT and CAR-T cell Therapies.pdf\u003c\/li\u003e\n\u003cli\u003eImmune Aging and Senolytics.mp4\u003c\/li\u003e\n\u003cli\u003eImmune Aging and Senolytics.pdf\u003c\/li\u003e\n\u003cli\u003eIncorporating Patient Reported Outcomes Into Standard of Care Practice.mp4\u003c\/li\u003e\n\u003cli\u003eIncorporating Patient Reported Outcomes Into Standard of Care Practice.pdf\u003c\/li\u003e\n\u003cli\u003eInfections as Toxicities Panel Discussions Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eIntegrating Patient Values and Preferences Into Treatment Decision Making.mp4\u003c\/li\u003e\n\u003cli\u003eIntegrating Patient Values and Preferences Into Treatment Decision Making.pdf\u003c\/li\u003e\n\u003cli\u003eMSKTox2023_Brochure.pdf\u003c\/li\u003e\n\u003cli\u003eNutrition and Microbiota in Allo-HCT.mp4\u003c\/li\u003e\n\u003cli\u003eNutrition and Microbiota in Allo-HCT.pdf\u003c\/li\u003e\n\u003cli\u003eNutrition – Microbiome and Toxicities Panel Discussion Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eNutritional Interventional Trial to Improve the Mircrobiome and Prevent Acute GVHD.mp4\u003c\/li\u003e\n\u003cli\u003eNutritional Interventional Trial to Improve the Mircrobiome and Prevent Acute GVHD.pdf\u003c\/li\u003e\n\u003cli\u003eParkinsonian Neurotoxicity After BCMA CAR T cells.mp4\u003c\/li\u003e\n\u003cli\u003eParkinsonian Neurotoxicity After BCMA CAR T cells.pdf\u003c\/li\u003e\n\u003cli\u003ePlant Sequencing and Gut Microbiome in Allo-HCT.pdf\u003c\/li\u003e\n\u003cli\u003ePost CAR T Cell Infections.mp4\u003c\/li\u003e\n\u003cli\u003ePost CAR T Cell Infections.pdf\u003c\/li\u003e\n\u003cli\u003ePulmonary Toxicities of Cellular Therapies.mp4\u003c\/li\u003e\n\u003cli\u003ePulmonary Toxicities of Cellular Therapies.pdf\u003c\/li\u003e\n\u003cli\u003eRemote Performance Status Monitoring Using Wearables and PROs.mp4\u003c\/li\u003e\n\u003cli\u003eRemote Performance Status Monitoring Using Wearables and PROs.pdf\u003c\/li\u003e\n\u003cli\u003eRespiratory Viral Infections- Acute and Persistent Lung Effects.mp4\u003c\/li\u003e\n\u003cli\u003eRespiratory Viral Infections- Acute and Persistent Lung Effects.pdf\u003c\/li\u003e\n\u003cli\u003eSpecial Luncheon Debate.mp4\u003c\/li\u003e\n\u003cli\u003eSpecial Luncheon Debate.pdf\u003c\/li\u003e\n\u003cli\u003eTransplant as a Model of Accelerated Aging.mp4\u003c\/li\u003e\n\u003cli\u003eTransplant as a Model of Accelerated Aging.pdf\u003c\/li\u003e\n\u003cli\u003eUpdates on the Diagnosis and Treatment of TA-TMA- Discussion with Experts.mp4\u003c\/li\u003e\n\u003cli\u003eUpdates on the Diagnosis and Treatment of TA-TMA- Discussion with Experts.pdf\u003c\/li\u003e\n\u003cli\u003eViral Specific T Cell Therapy for Polyomavirus- Overcoming BK and JC Virus After Cell Therapy.mp4\u003c\/li\u003e\n\u003cli\u003eViral Specific T Cell Therapy for Polyomavirus- Overcoming BK and JC Virus After Cell Therapy.pdf\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954409443426,"sku":"MED-AMB02946","price":60.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Memorial-Sloan-Kettering-Cancer-Center-3rd-International-Symposium-on-Biology-Prevention-and-Treatment-of-Toxicities-After-Transplantation-and-Cellular-Therapy-2023.jpg?v=1779375774","url":"https:\/\/meducourse.com\/products\/memorial-sloan-kettering-cancer-center-3rd-international-symposium-on-biology","provider":"Meducourse","version":"1.0","type":"link"}